A 32-year-old woman presents with severe dysmenorrhea and chronic pelvic pain for 3 years. Imaging shows multiple chocolate cysts in both ovaries with adhesions. She desires fertility preservation. What is the drug of choice for medical management of her endometriosis?

Explanation

## First-Line Medical Management of Endometriosis **Key Point:** GnRH agonists with add-back therapy are the gold standard for moderate-to-severe endometriosis, especially when fertility is a concern and symptom relief is the primary goal. ### Mechanism of Action GnRH agonists cause initial flare followed by downregulation of the pituitary-gonadal axis, resulting in profound hypogonadism and suppression of ovarian steroid production. This creates a "pseudo-menopausal" state that: - Suppresses endometrial growth and ectopic endometrial lesions - Reduces prostaglandin production - Alleviates dysmenorrhea and pelvic pain ### Add-Back Therapy Rationale Add-back hormones (norethisterone or tibolone) are co-prescribed to: - Prevent bone loss and vasomotor symptoms - Maintain quality of life during treatment - Preserve efficacy (progestin-only add-back does not compromise GnRH agonist effect) ### Treatment Duration & Outcomes - Standard duration: 3–6 months (can extend to 12 months with add-back) - Pain relief: 80–90% of patients - Lesion regression: 40–60% reduction in endometriotic implants - Fertility: No adverse effect on subsequent conception rates **High-Yield:** GnRH agonists are preferred over other medical options in moderate-to-severe disease because they provide superior pain control and lesion suppression while preserving ovarian reserve and future fertility potential. ### Why GnRH Agonist + Add-Back Over Alternatives? | Feature | GnRH Agonist + Add-Back | OCP | MPA | Danazol | |---------|------------------------|-----|-----|----------| | **Pain relief** | Excellent (80–90%) | Moderate (50–70%) | Good (60–80%) | Excellent but androgenic | | **Lesion regression** | 40–60% | Minimal | 30–40% | 40–50% | | **Bone safety** | Protected (add-back) | Safe | Safe | Safe | | **Androgenic effects** | None | None | Minimal | Significant | | **Fertility impact** | Neutral | Neutral | Neutral | Teratogenic risk | | **Cost** | High | Low | Low | Moderate | | **Severe disease** | First-line | Second-line | Second-line | Rarely used | **Clinical Pearl:** In this patient with chocolate cysts (ovarian endometriomas) and adhesions indicating severe disease, GnRH agonist with add-back is the evidence-based choice that maximizes symptom relief while maintaining reproductive potential.